The role of mannose-binding lectin (MBL) in diabetic retinopathy: A scoping review

IF 3.3 4区医学 Q3 IMMUNOLOGY

Immunology letters Pub Date : 2024-05-04 DOI:10.1016/j.imlet.2024.106863

Paula Basso Dias , Iara Messias-Reason , Kenzo Hokazono , Renato Nisihara

{"title":"The role of mannose-binding lectin (MBL) in diabetic retinopathy: A scoping review","authors":"Paula Basso Dias , Iara Messias-Reason , Kenzo Hokazono , Renato Nisihara","doi":"10.1016/j.imlet.2024.106863","DOIUrl":null,"url":null,"abstract":"<div><p>Diabetes mellitus (DM) is a chronic systemic disease characterized by a multifactorial nature, which may lead to several macro and microvascular complications. Diabetic retinopathy (DR) is one of the most severe microvascular complications of DM, which can result in permanent blindness. The mechanisms involved in the pathogenesis of DR are multiple and still poorly understood. Factors such as dysregulation of vascular regeneration, oxidative and hyperosmolar stress in addition to inflammatory processes have been associated with the pathogenesis of DR. Furthermore, compelling evidence shows that components of the immune system, including the complement system, play a relevant role in the development of the disease. Studies suggest that high concentrations of mannose-binding lectin (MBL), an essential component of the complement lectin pathway, may contribute to the development of DR in patients with DM. This review provides an update on the possible role of the complement system, specifically the lectin pathway, in the pathogenesis of DR and discusses the potential of MBL as a non-invasive biomarker for both, the presence and severity of DR, in addition to its potential as a therapeutic target for intervention strategies.</p></div>","PeriodicalId":13413,"journal":{"name":"Immunology letters","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2024-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunology letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165247824000373","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Diabetes mellitus (DM) is a chronic systemic disease characterized by a multifactorial nature, which may lead to several macro and microvascular complications. Diabetic retinopathy (DR) is one of the most severe microvascular complications of DM, which can result in permanent blindness. The mechanisms involved in the pathogenesis of DR are multiple and still poorly understood. Factors such as dysregulation of vascular regeneration, oxidative and hyperosmolar stress in addition to inflammatory processes have been associated with the pathogenesis of DR. Furthermore, compelling evidence shows that components of the immune system, including the complement system, play a relevant role in the development of the disease. Studies suggest that high concentrations of mannose-binding lectin (MBL), an essential component of the complement lectin pathway, may contribute to the development of DR in patients with DM. This review provides an update on the possible role of the complement system, specifically the lectin pathway, in the pathogenesis of DR and discusses the potential of MBL as a non-invasive biomarker for both, the presence and severity of DR, in addition to its potential as a therapeutic target for intervention strategies.

查看原文本刊更多论文

甘露糖结合凝集素（MBL）在糖尿病视网膜病变中的作用：范围综述。

糖尿病（DM）是一种慢性全身性疾病，具有多因素的特点，可导致多种宏观和微观血管并发症。糖尿病视网膜病变（DR）是糖尿病最严重的微血管并发症之一，可导致永久性失明。糖尿病视网膜病变的发病机制是多方面的，目前还不十分清楚。血管再生失调、氧化和高渗透压以及炎症过程等因素都与 DR 的发病机制有关。此外，令人信服的证据表明，免疫系统的组成部分，包括补体系统，在疾病的发展中发挥着相关作用。研究表明，高浓度的甘露糖结合凝集素（MBL）是补体凝集素通路的重要组成部分，它可能是导致糖尿病患者发生 DR 的原因之一。本综述介绍了补体系统，特别是凝集素通路在 DR 发病机制中可能扮演的角色的最新情况，并讨论了 MBL 作为一种非侵入性生物标志物的潜力，既可用于判断 DR 的存在和严重程度，也可作为干预策略的治疗目标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunology letters 医学-免疫学

CiteScore

7.60

自引率

0.00%

发文量

审稿时长

44 days

期刊介绍： Immunology Letters provides a vehicle for the speedy publication of experimental papers, (mini)Reviews and Letters to the Editor addressing all aspects of molecular and cellular immunology. The essential criteria for publication will be clarity, experimental soundness and novelty. Results contradictory to current accepted thinking or ideas divergent from actual dogmas will be considered for publication provided that they are based on solid experimental findings. Preference will be given to papers of immediate importance to other investigators, either by their experimental data, new ideas or new methodology. Scientific correspondence to the Editor-in-Chief related to the published papers may also be accepted provided that they are short and scientifically relevant to the papers mentioned, in order to provide a continuing forum for discussion.